Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

A Global Study of the PETAL Consortium

Massachusetts General Hospital · NCT06067347

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
1200
US sites recruiting
10
Study start
January 5, 2024
Record last updated
April 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or relapse, of mature T-cell and NK-cell neoplasms (TNKL). We hypothesize that machine learning can be leveraged to uncover distinct genetic vulnerabilities that underlie treatment response and resistance for patients with TNKL, thus moving towards personalized treatment solutions.

Conditions: T-Cell and NK-Cell Neoplasm

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Untreated, relapsed, or refractory histologically confirmed mature T-cell or NK-cell neoplasm.
  • All subtypes of PTCL are eligible except for T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma such as but not limited to mycosis fungoides and transformation, Sézary syndrome, and primary cutaneous CD30+ disorders.

Exclusion Criteria

  • Precursor T/NK neoplasms, T-cell large granular lymphocytic leukemia, cutaneous T-cell lymphoma such as but not limited to mycosis fungoides and transformation, Sézary syndrome, and primary cutaneous CD30+ disorders.
  • Adults who are unable to consent, individuals who are not yet adults such as infants, children and teenagers, pregnant women, and prisoners.

Recruiting US locations

  • City of Hope

    Duarte, CA 91010

    Site contact: Christina Poh Site Investigator, MD · (877) 302-3373 · cpoh@coh.org

  • University of Colorado

    Denver, CO 80204

    Site contact: (303) 315-5969 · bradley.haverkos@cuanschutz.edu

  • Moffitt Cancer Center

    Tampa, FL 33612

    Site contact: Yumeng Zhang, MD · (888) 663-3488 · Yumeng.Zhang@Moffitt.org

  • Massachusetts General Hospital

    Boston, MA 02114

    Site contact: Salvia Jain, MD · 650-224-0183 · salvia.jain@mgh.harvard.edu

  • Dana-Farber Cancer Institute

    Boston, MA 02215

    Site contact: Eric Jacobsen, MD · 877-442-3324 · eric_jacobsen@dfci.harvard.edu

  • Mayo Clinic

    Rochester, MN 55905

    Site contact: Nora Bennani, MD · (507) 284-2511 · Bennani.Nora@mayo.edu

  • Hackensack University Medical Center

    Hackensack, NJ 07601

    Site contact: Tatyana Feldman, MD · (201) 996-4300 · tatyana.feldman@hmhn.org

  • OhioHealth

    Columbus, OH 43214

    Site contact: Basem William Site Investigator, MD · (614) 544-4483 · Basem.William@ohiohealth.com

  • University of Pennsylvania

    Philadelphia, PA 19104

    Site contact: Stefan Barta, MD · 215-898-5000 · stefan.barta@pennmedicine.upenn.edu

  • University of Virginia

    Charlottesville, VA 22903-4

    Site contact: Enrica Marchi, MD · +1 434-924-0311 · EM5YT@uvahealth.org

Study contacts (from the official record)

  • Salvia Jain, MD · 650-224-0183 · salvia.jain@mgh.harvard.edu
  • Forum Bhanushali · 857-757-0966 · fbhanushali@bwh.harvard.edu
All healthy volunteers studies in California →
A Global Study of the PETAL Consortium (NCT06067347) | Bored Studies